newsfilter
← Latest News
ACCESS Newswire·

Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - S